Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The Coca-Cola Company ( KO - Analyst Report ) is set to report fourth quarter and full year 2012 results on Feb 12 before the market opens. Last quarter it posted a 2% positive surprise. Let’s see how things are shaping up for this announcement.
Growth Factors This Past Quarter
Though earnings beat the Zacks Consensus Estimates in the third quarter, they were below the year-ago levels due to lukewarm revenues and weak profits. Revenues increased only 1% in the quarter as benefits from volume growth was largely offset by currency headwinds and a flat price/mix. Volumes improved in the quarter due to balanced growth across the developed and emerging markets.
Earnings Whisper
The fourth quarter Zacks Consensus Earnings Estimate stands at 44 cents. Estimates have mostly seen a downward trend ahead of the fourth quarter earnings release. This may be due to persistent weakness seen in the overall carbonated soft drinks’ (CSD) volumes in North America since the past few months.
Changing consumer preferences, increasing health consciousness and growing regulatory pressures are affecting sparkling beverage sales. This is hurting CSD volumes for Coca-Cola as well as other beverage companies like PepsiCo, Inc. ( PEP - Analyst Report ) .
Moreover, management is expecting fourth quarter adjusted gross margin to be lower than both the second and third quarter margin of 60.3%, mainly due to the currency and mix shift headwinds. Foreign exchange is expected to unfavorably impact operating income in the mid-single-digit range. However, profits are expected to accelerate in the fourth quarter as operating expense leverage is expected to be better in the quarter due to 2 additional selling days.
The stock carries a Zacks Rank #4 (Sell). We caution against stocks with Zacks Ranks #4 and #5 (Sell rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions momentum.
Other Stocks to Consider
Our model states that a stock needs to have both a positive Earnings ESP (Read: Zacks Earnings ESP: A Better Method) and a Zacks Rank of #1, #2 or #3 to beat earnings estimates. You could, however, consider other consumer staples stocks like:
Coca-Cola FEMSA S.A.B de C.V. ( KOF - Snapshot Report ) , with Earnings ESP of +7.87% and a Zacks Rank #2 (Buy)
Kellogg Company ( K - Analyst Report ) , with an Earnings ESP of +0.97% and a Zacks Rank #2 (Buy)
Read the full reports :
Analyst Report on KO
Analyst Report on PEP
Analyst Report on K
Snapshot Report on KOF